Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Schiff, Rachel ^a   Massarweh, Suleiman ^a   Shou, Jiang ^a   Osborne, C Kent ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CELL NUCLEUS RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REGULATOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; TREATMENT FAILURE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GROWTH SUBSTANCES; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 0037237481     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Lacassagne, A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer. 27: 217-225, 1936.
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet, 339: 71-85, 1992.
3. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359: 2131-2139, 2002.
5. Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 339: 1609-1618, 1998.
6. Howell, A., DeFriend, D., Robertson, J., Blamey, R., and Walton, P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 29-30, 1995.
7. Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V., and DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl. Cancer Inst. (Bethesda), 83: 1477-1482, 1991.
8. Osborne, C. K., and Fuqua, S. A. Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat., 32: 49-55, 1994.
9. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., and Wakeling, A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol., 34: 89-95, 1994.
10. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
11. Legault-Poisson, S., Jolivet, J., Poisson, R., Beretta-Piccoli, M., and Band. P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep., 63: 1839-1841, 1979.
12. Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 746-750, 1995.
13. Katzenellenbogen, B. S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54: 287-293, 1996.
14. Osborne, C. K., Zhao, H., and Fuqua, S. A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol., 18: 3172-3186, 2000.
15. Palmieri, C., Cheng, G. J., Saji, S., Zelada-Hedman, M., Warri, A., Weihua, Z., Van Noorden, S., Wahlstrom, T., Coombes, R. C., Warner, M., and Gustafsson, J. A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer, 9: 1-13, 2002.
16. Kumar, R., and Thompson, E. B. The structure of the nuclear hormone receptors. Steroids, 64: 310-319, 1999.
17. Jensen, E. V. Overview of the nuclear receptor family. In: M. G. Parker (ed.), Nuclear Hormone Receptors: Molecular Mechanisms, Cellular Functions, Clinical Abnormalities, pp. 1-13. London: Academic Press, 1991.
18. Katzenellenbogen, B. S., Choi, I., Delage-Mourroux, R., Ediger, T. R., Martini, P. G., Montano, M., Sun, J., Weis, K., and Katzenellenbogen, J. A. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol., 74: 279-285, 2000.
19. Schiff, R., and Fuqua, S. A. W. The importance of the estrogen receptor in breast cancer. In: P. JR (ed.), Breast Cancer: Prognosis, Treatment, and Prevention, pp. 149-186. New York, Basel: Marcel Dekker, Inc., 2002.
20. McInerney, E. M., and Katzenellenbogen, B. S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J. Biol. Chem., 271: 24172-24178, 1996.
21. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol., 74: 311-317, 2000.
22. Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J. A., and Safe, S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem., 275: 5379-5387, 2000.
23. Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M., Beato, M., Sica, V., Bresciani, F., and Weisz, A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
24. Montano, M. M., and Katzenellenbogen, B. S. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc. Natl. Acad. Sci. USA, 94: 2581-2586, 1997.
25. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science, 277: 1508-1510, 1997.
26. Duval, D., Durant, S., and Homo-Delarche, F. Non-genomic effects of steroids. Interactions of steroid molecules with membrane structures and functions. Biochem. Biophys. Acta, 737: 409-442, 1983.
27. Kelly, M. J., and Levin, E. R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab., 12: 152-156, 2001.
28. Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and Yue, W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol., 80: 239-256, 2002.
29. Speirs, V., and Kerin, M. J. Prognostic significance of oestrogen receptor beta in breast cancer. Br. J. Surg., 87: 405-409, 2000.
30. Speirs, V., Malone, C., Walton, D. S., Kerin, M. J., and Atkin, S. L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res., 59: 5421-5424, 1999.
31. McKenna, N. J., Lanz, R. B., and O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev., 20: 321-344, 1999.
32. Delage-Mourroux, R., Martini, P. G., Choi, I., Kraichely, D. M., Hoeksema, J., and Katzenellenbogen, B. S. Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J. Biol. Chem., 275: 35848-35856, 2000.
33. Smith, C. L., Nawaz, Z., and O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol., 11: 657-666, 1997.
34. Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L., and Horwitz, K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol., 11: 693-705, 1997.
35. Szapary, D., Huang, Y., and Simons, S. S., Jr. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol. Endocrinol., 13: 2108-2121, 1999.
36. Liu, Z., Auboeuf, D., Wong, J., Chen, J. D., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA. 99: 7940-7944, 2002.
37. Masamura, S., Santner, S. J., Heitjan, D. F., and Santen, R. J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab., 80: 2918-2925, 1995.
38. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature, 377: 397-404, 1995.
39. Chen, J. D., and Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature, 377: 454-457, 1995.
40. Sande, S., and Privalsky, M. L. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol. Endocrinol., 10: 813-825, 1996.
41. Graham, J. D., Bain, D. L., Richer, J. K., Jackson, T. A., Tung, L., and Horwitz, K. B. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J. Steroid Biochem. Mol. Biol., 74: 255-259, 2000.
42. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA, 95: 2920-2925, 1998.
43. McKenna, N. J., and O'Malley, B. W. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol., 74: 351-356, 2000.
44. Wu, R. C., Qin, J. Hashimoto, Y., Wong, J., Xu, J., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase. Mol. Cell. Biol., 22: 3549-3561, 2002.
45. Leo, C., and Chen, J. D. The SRC family of nuclear receptor coactivators. Gene, 245: 1-11, 2000.
46. Chang, C., Norris, J. D., Gron, H., Paige, L. A., Hamilton, P. T., Kenan, D. J., Fowlkes, D., and McDonnell, D. P. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell. Biol., 19: 8226-8239, 1999.
47. Ko, L., Cardona, G. R., Iwasaki, T., Bramlett, K. S., Burris, T. P., and Chin, W. W. Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Mol. Endocrinol., 16: 128-140, 2002.
48. Shang, Y., and Brown, M. Molecular determinants for the tissue specificity of SERMs. Science, 295: 2465-2468, 2002.
49. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science, 277: 965-968, 1997.
50. Murphy, L. C., Simon, S. L., Parkes, A., Leygue, E., Dotzlaw, H., Snell, L., Troup, S., Adeyinka, A., and Watson, P. H. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res., 60: 6266-6271, 2000.
51. List, H. J., Reiter, R., Singh, B., Wellstein, A., and Riegel, A. T. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res. Treat., 68: 21-28, 2001.
52. Xu, J., Liao, L., Ning, G., Yoshida-Komiya, H., Deng, C., and O'Malley, B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. USA, 97: 6379-6384, 2000.
53. List, H. J., Lauritsen, K. J., Reiter, R., Powers, C., Wellstein, A., and Riegel, A. T. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem., 276: 23763-23768, 2001.
54. Webb, P., Nguyen, P., Shinsako, J., Anderson, C., Feng, W., Nguyen, M. P., Chen, D., Huang, S. M., Subramanian, S., McKinemey, E., Katzenellenbogen, B. S., Stallcup, M. R., and Kushner, P. J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol., 12: 1605-1618, 1998.
55. Nicholson, R. I., McClelland, R. A., Robertson, J. F., and Gee, J. M. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer, 6: 373-387, 1999.
56. Lee, A. V., Cui, X., and Oesterreich, S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res., 7: 4429s-4435s; discussion 4411s-4412s, 2001.
57. Nicholson, R. I., Gee, J. M. W., Barrow, D., Pamment, J. S., Knowlden, J. M., and McClelland, R. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 1999.
58. Ali, S., Metzger, D., Bornert, J. M., and Chambon, P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J., 12: 1153-1160, 1993.
59. Le Goff, P., Montano, M. M., Schodin, D. J., and Katzenellenbogen, B. S. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem., 269: 4458-4466, 1994.
60. Joel, P. B., Smith, J., Sturgill, T. W., Fisher, T. L., Blenis, J., and Lannigan, D. A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol., 18: 1978-1984, 1998.
61. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 270: 1491-1494, 1995.
62. Lee, H., Jiang, F., Wang, Q., Nicosia, S. V., Yang, J., Su, B., and Bai, W. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol., 14: 1882-1896, 2000.
63. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., and Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J. Biol. Chem., 276: 9817-9824, 2001.
64. Font de Mora, J., and Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol., 20: 5041-5047, 2000.
65. Lopez, G. N., Turck, C. W., Schaufele, F., Stallcup, M. R., and Kushner, P. J. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J. Biol. Chem., 276: 22177-22182, 2001.
66. Puigserver, P., Rhee, J., Lin, J., Wu, Z., Yoon, J. C., Zhang, C. Y., Krauss S., Mootha, V. K., Lowell, B. B., and Spiegelman, B. M. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol. Cell, 8: 971-982, 2001.
67. Rowan, B. G., Garrison, N., Weigel, N. L., and O'Malley, B. W. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cell. Biol., 20: 8720-8730, 2000.
68. Lazennec, G., Thomas, J. A., and Katzenellenbogen, B. S. Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators. J. Steroid Biochem. Mol. Biol., 77: 193-203, 2001.
69. Schiff, R., Reddy, P., Ahotupa, M., Coronado-Heinsohn, E., Grim, M., Hilsenbeck, S. G., Lawrence, R., Deneke, S., Herrera, R., Chamness, G. C., Fuqua, S. A., Brown, P. H., and Osborne, C. K. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. (Bethesda), 92: 1926-1934, 2000.
70. Shou, J., Weigel, N. L., Osborne, C. K., and Schiff, R. Onset of endocrine resistance in breast cancer is associated with increased active p38 MAPK. In: 24th San Antonio Breast Cancer Symposium, San Antonio, 2001, pp. 254 (Abstract).
71. Atanaskova, N., Keshamouni, V. G., Krueger, J. S., Schwartz, J. A., Miller, F., and Reddy, K. B. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene, 21: 4000-4008, 2002.
72. Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
73. Hong, S. H., and Privalsky, M. L. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol. Cell. Biol., 20: 6612-6625, 2000.
74. Piccart, M., Lohrisch, C., Di Leo, A., and Larsimont, D. The predictive value of HER2 in breast cancer. Oncology, 61: 73-82, 2001.
75. Lupu, R., Cardillo, M., Cho, C., Harris, L., Hijazi, M., Perez, C., Rosenberg, K., Yang, D., and Tang, C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res. Treat., 38: 57-66, 1996.
76. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
77. Mass, R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol., 27: 46-52; discussion 92-100, 2000.
78. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer, 8: 191-195, 2001.
79. th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 2002, pp. 33a (Abstract 129).